☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Drug Safety Update - August 2016

The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for August 2016 (PDF).

Following early termination of a clinical trial it is recommended that riociguat (Adempas®) should not be used to treat patients with pulmonary hypertension associated with idiopathic interstitial pneumonias. This medication should be under specialist supervision.

There is also a summary of letters sent to healthcare professionals in July including a letter advised that posaconazole (Noxafil®) tablets and suspension are not interchangeable and that inadvertent changes between the two formulations has led to under-dosing or over-dosing.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'Drug Safety Update - August 2016' by emailShare 'Drug Safety Update - August 2016' on FacebookShare 'Drug Safety Update - August 2016' on TwitterShare 'Drug Safety Update - August 2016' on LinkedInShare 'Drug Safety Update - August 2016' on reddit


One Comment to “Drug Safety Update - August 2016”

  1. […] This issue also contains additional information that posaconazole suspension and tablets are not dose equivalent as noted in the summary of letters to healthcare professionals in last month's update. […]

    Pingback by Drug Safety Update - September 2016 - Prescribing Advice for GPs — September 19, 2016 #

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.